|Articles|July 1, 2003
Efficacy of Alefacept Treatment in Chronic Plaque Psoriasis
Alefacept is a human LFA-3/IgG1 fusion protein incorporating the external domain of LFA-3, which is expressed on the surface of APCs.4 Alefacept acts by blocking the interaction between LFA-3 and CD2 on the surface of T cells, thereby interfering with the costimulatory step of T-cell activation.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
2
Transformative Advances This Year and Beyond
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5














